Clinical-stage biotechnology company developing novel treatments for autoimmune diseases.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company dedicated to pioneering the discovery and development of innovative small molecule therapeutics. Focused on addressing significant unmet medical needs in immune-mediated diseases and cancer, the company leverages cutting-edge research to advance its therapeutic pipeline.
At the forefront of Kezar's pipeline is KZR-616, a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials. This lead product candidate shows promise for treating a range of indications, including lupus nephritis, dermatomyositis, and polymyositis. Additionally, KZR-616 is in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis, demonstrating its potential to address critical autoimmune conditions.
Kezar Life Sciences also pursues preclinical development of innovative products. Among these is KZR-261, a novel protein secretion inhibitor anticipated to offer a pioneering treatment approach. Additionally, KZR-TBD, another preclinical candidate, holds promise for applications in both oncology and immunology, further underscoring the company's commitment to advancing therapeutic options.
Founded in 2015 and headquartered in South San Francisco, California, Kezar Life Sciences blends scientific expertise with a dedication to transformative medicine. By pushing the boundaries of small molecule therapeutics, Kezar aims to make significant strides in improving patient outcomes across diverse disease areas.